Five of the latest advancements in NASH research
Welcome to the 110 new subscribers who joined our LinkedIn newsletter last week ?? If not done yet, subscribe to join the 4,270 fans of the Pick of the Week!
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) – a condition where fat builds up in the liver, potentially causing liver damage or cirrhosis.?
However, despite the severity of this disease, there is still currently no FDA-approved treatment for the condition.
The standard recommendations for managing NASH simply involve making lifestyle changes, and, until recently, the main focus of NASH research was ultimately to prevent the progression of the disease into cirrhosis.
But things are beginning to change, with new NASH drugs showing success in clinical trials, and a new-found wave of attention has meant that plenty of research has been conducted recently surrounding the condition.
Therefore, this week we have put together a list of some of the latest advancements in NASH research.
To find out more, read the full article: "Five latest advancements in NASH research"
?? More noteworthy articles from this week:
领英推荐
After more than two years of being shut out due to post Brexit tensions, the U.K. is now rejoining the EU’s $100 billion research program Horizon Europe, in an attempt to broaden opportunities for researchers in the U.K.
Although mainly known for being home to the iconic Hollywood, in recent years Los Angeles has also become a thriving biotech hub that could now even rival the likes of South San Francisco and Boston within the U.S. biotech space.
After several years of multinational biotech company Thermo Fisher using Henrietta Lacks’ cells without seeking consent, Lacks’ family finally got justice as they settled a lawsuit with the biotech giant.
Despite recent progress in therapeutic options for autoimmune disorders, a significant unmet need still remains, which is why Swiss startup Mysthera Therapeutics is aiming to take on these diseases using the unique approach of PIM kinase inhibition.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community!?Click here?to join our mailing list.